Available Until 10/31/2025
View Cart

Opioid REMS Education: A Guide for the Interprofessional Team in Achieving Comprehensive Pain Management

ACPE Number: 0204-0000-24-407-H08-P
Content Release Date: 10/23/2024
Content Expiration Date: 10/31/2025
Activity Type: Application-based
CE Credits: 2.0 contact hours
Activity Fee: Free

This is a recording of a live webinar. Those who claimed credit for the live webinar, should not claim credit for the home study.

Activity Overview

This educational activity is highly relevant to clinicians who frequently practice as part of the interprofessional team in treating patients with pain in hospitals, health systems and ambulatory care centers. Not all clinicians are intimately familiar with the FDA’s Opioid Analgesic Risk Evaluation and Mitigation Strategy (REMS), which is essential in order to ensure that patients receive and understand the Medication Guides and information regarding the safe use of these products. With enhanced knowledge and strategies for managing patients with pain, clinicians can support the interprofessional team in addressing opioid addiction and support the safe use of opioids.  

ACPE Provider with Commendation logo

The American Society of Health-System Pharmacists is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education with Commendation.

The American Society of Health-System Pharmacists is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. 

The American Society of Health-System Pharmacists designates this live activity for a maximum of 2.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. 

    The target audience for these educational activities is physicians, pharmacists, physician associates and nurse practitioners (prescribers and non-prescribers involved in the care of patients receiving opioid analgesic therapy, nonpharmacologic therapies, and non-opioid medication therapies). 

    1. Describe the importance of health care provider education in the FDA’s opioid REMS program.
    2. Discuss the fundamentals of pain management, including definitions, etiology, assessment, diagnosis, and mechanisms of pain.
    3. Evaluate multi-modal therapeutic options for managing pain.
    4. Develop individualized pain management plans that include therapy goals, pharmacologic and non-pharmacologic options, and interprofessional collaboration.
    5. Apply strategies on the safe use of opioid therapy, including counseling patients and caregivers on their use, as well as proper storage and disposal of the medications.
    6. Develop an approach for identifying and managing patients with opioid use disorder.

    Welcome and Introductions
    Timothy Atkinson

    Fundamentals of Pain Management
    Charles E. Argoff

    Optimizing Pain Management
    Timothy Atkinson

    Meeting the Challenges of Chronic Pain Management and Opioid Use Disorder
    Christopher M. Herndon

    Question and Answer
    All Faculty

    Timothy Atkinson, PharmD, CPE, Activity Chair
    Clinical Pharmacy Practitioner, Pain Management
    Federal Facility
    Nashville, Tennessee 

    Christopher M. Herndon, PharmD, BCACP, FASHP, FCCP
    Professor - Southern Illinois University Edwardsville
    Advanced Practice Pharmacist, Pain -
    SIHF Healthcare
    Edwardsville, Illinois

    Charles E. Argoff, MD
    Professor of Neurology
    Albany Medical College
    Director, Pain Management Fellowship
    Albany, New York

    In accordance with our accreditor’s Standards of Integrity and Independence in Accredited Continuing Education, ASHP requires that all individuals in control of content disclose all financial relationships with ineligible companies. An individual has a relevant financial relationship if they have had a financial relationship with an ineligible company in any dollar amount in the past 24 months and the educational content that the individual controls is related to the business lines or products of the ineligible company. 

    An ineligible company is any entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients. The presence or absence of relevant financial relationships will be disclosed to the activity audience. The following persons in control of this activity’s content have relevant financial relationships:

    • Christopher M. Herndon: Perrigo – direct ownership of stock
    • Charles E. Argoff:
      • Clinical trial investigator: Vertex, Lundbeck, AbbVie
      • Speaker’s bureau: AbbVie, Scilex, Lundbeck
      • Consultant: Scilex, Xgene, Lundbeck

    All other persons in control of content do not have any relevant financial relationships with an ineligible company. As defined by the Standards of Integrity and Independence in Accredited Continuing Education definition of ineligible company. All relevant financial relationships have been mitigated prior to the CE activity.

    This activity consists of the following:

    • A pre-assessment completed prior to viewing the home study
    • A faculty slide presentation with active learning and faculty discussion
    • Supplementary materials
    • A post-assessment (a score of at least 70% is required)
    • An evaluation

    Participants must participate in the activity in its entirety to claim continuing pharmacy education credit online at the ASHP eLearning Portal. Follow the prompts to complete the post-assessment and evaluation, claim credit, and view the statement of credit immediately after completing the activity.

    Claim CE Within 60 Days

    Per ACPE requirements, CPE credit must be claimed within 60 days of being earned. Claim CE (enter the CE code announced during activity and complete the evaluation).

    Once you have processed and claimed your CE credit, we encourage you to check your ​NABP eProfile account to verify that your credit has posted before the ACPE 60-day deadline.

    After ACPE's 60 day deadline, ASHP will no longer be able to report credits for this activity. 

    There is also an option to download an ASHP Statement of Completion for this REMS-compliant activity.

    Provided by ASHP

    This activity is supported by an independent educational grant from the Opioid Analgesic REMS Program Companies (RPC). Please see https://www.opioidanalgesicrems.com/Resources/Docs/List_of_RPC_Companies.pdf for a listing of REMS Program Companies. This activity is intended to be fully compliant with the Opioid Analgesic REMS education requirements issued by the US Food & Drug Administration (FDA).